focus -WSS

focus

author：explore 2025-09-28 02:41:52 Page View：1

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： NIH director takes cautious approach to Biden drug pricing priority
Next article： Sports medicine is finally prioritizing gender equality

comprehensive

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

UnitedHealthGroupisattemptingtobuyAmedisysfor$3.3billion.CourtesyUnitedHealthGroupThere’snowatwo-par

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Brazil's Jair Bolsonaro is barred from running for office until 2030

MinisteroftheSupremeElectoralCourtCarmenLucia,right,talkswithCorregidorandMinisterRapporteurBenedito